Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Bibliographic Details
Published in:	Breast Cancer Research Vol. 25; no. 1; pp. 1 - 11
Main Authors:	Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Zarate, J. P., Wang, Y., Chakravartty, A., Wang, C., Slamon, D. J.
Format:	Journal Article
Published:	BioMed Central 8/31/2023
Online Access:	View this record in EBSCOhost